Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.

Abstract: The invention provides pro insulin c-peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.

Abstract: The invention provides nesiritide that is chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of nesiritide not attached to the water-soluble oligomer.

Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.

Abstract: The present invention provides a target gene-specific histone modification regulator, which comprises a conjugate between a histone modification regulator and a polyamide capable of recognizing a regulatory region in a target gene. This enables the provision of a target gene-specific histone modification regulator.

Abstract: A biocompatible, biodegradable, macromolecular water-absorbent hybrid material (WAHM), having a three-dimensional configuration with intermolecular covalent bonds and containing free functional groups, said polymer being formed by polymer-polymer intercoupling reaction between a natural water-soluble polymer A or its derivatives having a molecular weight between 20,000 and 300,000 Da, and a synthetic polymer B in an adequate ratio wherein the natural polymer A is selected from amphoteric reactants, partially denatured or chemically modified natural polymer, that dissociates in water to form both anions and cations, and which can undergo polymer-polymer intercoupling reactions, and wherein synthetic polymer B is a linear or branched reactive synthetic copolymer having a molecular weight of 50,000-500,000 Da derived from a vinyl monomer and an ethylenically unsaturated monomer, having a backbone with polymeric subunits covalently bonded to the polymer backbone, the subunits comprising ones with non-reactive and

Abstract: A biodegradable cationic polymer is disclosed, comprising first repeat units derived from a first cyclic carbonyl monomer by ring-opening polymerization, wherein more than 0% of the first repeat units comprise a side chain moiety comprising a quaternary amine group; a subunit derived from a monomeric diol initiator for the ring-opening polymerization; and an optional endcap group. The biodegradable cationic polymers have low cytotoxicity and form complexes with biologically active materials useful in gene therapeutics and drug delivery.

Abstract: N-hydroxysuccinimide acrylate ester monomers are described which provide N-hydroxysuccinimide derivatized monomers for the formation of polymeric cell culture surfaces suitable for culture of difficult to culture cells including undifferentiated embryonic stem cells. Methods of making the monomers and are also described.

Abstract: Conjugates of polypeptides and a polymeric moiety such as PEG covalently attached to the sulfur atom of a methionine side chain are disclosed. Processes of preparing such conjugates, including intermediates and reagents utilized therefore are also disclosed. Further disclosed are therapeutic uses of these conjugates.

Abstract: Compositions and methods for diagnosis and treatment of ALS are provided.

Abstract: The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.

Abstract: The present invention relates to a set of polymer particles stained with at least two fluorescent dyes, wherein at least 16 subsets of particles can be resolved on the basis of variable emission from the at least two fluorescent dyes wherein emission from at least one dye derives from a fluorescent dye covalently attached to the particle surface, and wherein all particles in said set of polymer particles can bind a uniform amount of a capture reagent. The invention also relates to a method for the preparation of said set of polymer particles as well as a kit comprising said set of polymer particles. The invention further relates to methods and uses of said set of polymer particles.

Abstract: Isolated glycan binding peptide complex comprise two or more glycan binding peptides operatively coupled to each other. These are bacterial binding peptide conjugates (e.g., glycan binding peptides) to a multivalent polymer (e.g., a multivalent PEG molecule) or to the surface of particles that create multimeric constructs that inhibit growth and aggregation of microbes. Included is a method of evaluating a substance for the presence of a microbe comprising contacting the substance with a peptide microarray or a peptide complex comprising a plurality glycan binding peptide operatively coupled to a substrate or multivalent linker, wherein the glycan binding peptide is coupled to an array by a linker that is at least 0.5 micrometers in length.

Abstract: The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.

Abstract: Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses.

Abstract: Compositions comprising a fluorinated polymer and related methods.

Abstract: Disclosed is a microanalysis chip adhesive sheet with an adhesive surface, which can be inexpensively but easily bonded to a substrate at a relatively low temperature, with which fabrication of analysis chips is simplified, and which has the capability of fixing a selective bonding substance to the sheet surface. The microanalysis chip is characterized in that a microanalysis chip adhesive sheet, which comprises a plastic sheet provided with an adhesive layer formed from an adhesive that contains a polymer in which monomer structural units that contain carboxyl radicals or acid anhydride radicals constitute 5-25% by weight of the [total] monomer structural units in the polymer, and a substrate, which has protrusions and recesses on the surface thereof, are bonded together so that the surface of the substrate having the projections and concavities and the adhesive layer of the aforementioned microanalysis chip adhesive sheet are on the inside.

Abstract: Polymer bioconjugate having a RNAi agent covalently coupled to the alpha or omega end of a pH-dependent membrane-destabilizing polymer.

Abstract: Disclosed are new recombinant nucleic acids encoding protein A polypeptides and methods of using these nucleic acids.

Abstract: The present disclosure provides novel functional polyoxazoline derivatives prepared by terminating polyoxazoline polymerization with inert chemical groups. In addition, the present disclosure demonstrates the synthesis of novel electrophilic initiators with protected functional groups capable of initiating oxazoline polymerization and capable of surviving the conditions of polymerization. These initiators are used to synthesize the above inert-terminal polyoxazoline derivatives as well as other poly-oxazolines with active terminal groups. Furthermore, the present disclosure provides for polyoxazoline-lipid conjugates and liposomal compositions prepared using such polyoxazoline-lipid conjugates. Methods of using the foregoing to prepare conjugates with target molecules are also disclosed.

Abstract: The invention relates to a biomaterial having a latent form of a growth factor immobilised thereon, and to a method of producing the biomaterial, comprising immobilising the latent form of the growth factor on the biomaterial. The biomaterial may be used in medicine, such as in tissue regeneration or repair.

Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.

Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.

Abstract: The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker.

Abstract: Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and an oligoaspartate bone targeting agent, and processes of preparing same, are further disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment and monitoring of bone related disorders are also disclosed.

Abstract: The present invention relates a method of making a coated cellulosic textile, whereby a silk peptide is polymerized with a building block to develop a silk peptide/building block nanoparticle, said nanoparticle then being used to coat the textile. The resultant textile exhibits a high level of wrinkle recovery angle and/or tear strength, all without the use of N-methylol compounds, including ureas and formaldehydes.

Abstract: The invention provides reagents and methods for conjugating a polymer specifically to the ?-amine of a polypeptide. The invention provides monofunctional, bifunctional, and multifunctional PEGs and related polymers having a terminal thioester moiety capable of specifically conjugating to the ?-amine of a polypeptide having a cysteine or histidine residue at the N-terminus. The invention provides reactive thioester-terminated PEG polymers that have suitable reactivity with an N-terminal cysteine or histidine residue of a polypeptide to produce an amide bond between the PEG molecule and the polypeptide.

Abstract: The present invention concerns a delivery system administered to the lung preferably by inhalation comprising a polymer-based nanoparticle; and a linker comprising a first portion non-covalently anchored to said nanoparticle, wherein at least part of said first portion comprises a hydrophobic/lipophilic segment embedded in said nanoparticle; and a second portion comprising a coupling group, preferably a maleimide compound, exposed at the outer surface of said nanoparticle. In accordance with one embodiment, the delivery system comprises one or more targeting agents, each covalently bound to said coupling group, preferably maleimide compound, and is administered as an aerosol in the therapy or diagnosis of lung cancer or bronchial dysplasia. In accordance with yet another embodiment, the delivery system comprises a drug and/or a radiopharmaceutical and/or a contrasting agent. A specific example for a linker in accordance with the invention is octadecyl-4-(maleimideomethyl)cyclohexane-carboxylic amide (OMCCA).

Abstract: Substrates for cell culture and tissue engineering bioreactors consisting of polymers that change their shape over time under stimulation by temperature change, hydration, degradation, or other means. A method of controlling cell culture using a biodegradable shape memory polymer, wherein shape changes can transfer stresses, strains, or both to adherent or otherwise connected cells such that the mechanical stimulus impacts cell development and the resulting properties of tissues.

Abstract: A conjugate of a randomly and asymmetrically branched dendritic polymer and a member of a binding pair.

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.

Abstract: The invention provides a surface, wherein said surface comprises (i) a polymer substrate and (ii) sugar groups and peptide groups coupled to said substrate suitable for culturing hepatocytes.

Abstract: The invention further relates to polycationic multichromophores, which may be conjugated polymers, and methods, articles and compositions employing them as described herein. In some aspects, the invention relates to methods, articles and compositions for the detection and analysis of biomolecules in a sample. Provided assays include those determining the presence of a target biomolecule in a sample or its relative amount, or the assays may be quantitative or semi-quantitative. The methods can be performed on a substrate. The methods can be performed in an array format on a substrate, which can be a sensor. In some embodiments, detection assays are provided employing sensor biomolecules that do not comprise a fluorophore that can exchange energy with the cationic multichromophore.

Abstract: The invention relates to novel biodegradable materials which are based on modified polyamino acids and which can be used for the vectorisation of active principle(s) (AP). The invention also relates to novel pharmaceutical, cosmetic, dietary or phytosanitary compositions based on said polyamino acids. The aim of the invention is to provide a novel polymer raw material which can be used for the vectorisation of active principles and which can optimally fulfil all required specifications in said area, namely: biocompatibility, biodegradability and the ability to become easily associated with many active principles or to solubilise said principles and to release same in vivo. Said aim is achieved with novel copolyhydroxyalkylglutamines comprising glutamine units and optionally glutamate units and bearing hydrophobic groups containing between 8 and 30 carbon atoms.

Abstract: A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the fibrinogen in a pharmacokinetically regulated manner, thereby treating the disorder characterized by tissue damage or malformation.

Abstract: An object of the present invention is to provide a method of immobilizing the biologically active substance which has an excellent capability of immobilizing a target biologically active substance, and exhibits low nonspecific adsorption of the biologically active substance to provide a high S/N ratio, without using a functional group for fixing the biologically active substance and without having a process of inactivating the functional group for fixing the biologically active substance after immobilizing the biologically active substance. The above object is achieved by a method of immobilizing a biologically active substance comprising the step of: bringing a solution into contact with a compound-side surface of an immobilizing substrate to immobilize the biologically active substance on a surface of the immobilizing substrate, the solution being prepared by dissolving the biologically active substance in a phosphate buffer having a phosphate concentration of 0.

Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.

Abstract: A coated microcarrier for cell culture includes a microcarrier base and a polymeric coating grafted to the base via a polymerization initiator. A method for forming the coated microcarrier includes (i) conjugating a polymerization initiator to the microcarrier base to form an initiator-conjugated microcarrier base; (ii) contacting the initiator-conjugated microcarrier base with monomers; and (iii) activating the initiator to initiate polymerization and graft the polymer to the base.

Abstract: A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.

Abstract: The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.

Abstract: Modified FGF-23 polypeptides and uses thereof are provided.

Abstract: This invention relates to a peptide nucleic acid (PNA) oligomer which is conjugated with one or more linear-type amino acid containing a plurality of alkyleneglycols and to a synthesis method thereof. In addition, this invention related to a linear amino acid spacer in a device for detection for detecting a target gene using the PNA oligomers which is fixed on a surface of a functionalized solid support. The linear amino acid spacer contains a plurality of alkyleneglycols and maintains enough space between the solid support and PNA oligomer in the device in order to prevent the interference of the interaction between the PNA oligomer and a target gene. Furthermore, this invention relates to a PNA array, a PNA chip and a gene diagnosis kit whereof sensitivity and specificity are improved by being manufactured with the PNA conjugated with the amino acid spacer.

Abstract: Degradable complexes comprising a polycation, a polyanion and a polynucleotide are useful for in vivo polynucleotide delivery applications.

Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.

Abstract: Described herein are polymer-coated substrates for binding biomolecules and methods of making and using thereof.

Abstract: The present invention relates to synthetic methods for grafting hydrophilic chains onto polymers, particularly hydrophobic polymers such as poly(vinyl chloride) (PVC), poly(vinylidene fluoride) (PVDF), and chlorinated polypropylene (cPP). Resulting polymers include comb polymers which can have a microphase-separated structure of hydrophilic domains provided by the hydrophilic chains. Articles prepared from these comb polymers, particularly derived from PVDF, include membranes for water filtration in which the hydrophilic domains provide a pathway for water transport. PVC can be plasticized by grafting the PVC with hydrophilic chains. In addition, such articles, particularly articles having biomedical applications, can display anti-thrombogenic properties.

Abstract: Biomimetic polymer networks comprising a heteropolymer network having a cavity, the cavity having a selective affinity for a moiety, methods for making biomimetic polymer networks, and methods for using biomimetic polymer networks.

Abstract: A body fluid compatible and biocompatible resin for use in a medical treatment involving a contact of said resin with at least one member selected from the group consisting of a body fluid and a biological tissue, which comprises at least one substituted oxyalkylene polymer having a weight average molecular weight of from 1,000 to 1,000,000 and represented by the following formula (1): wherein each of R1, R2 and R3 independently represents a hydrogen atom or a —CH2R4 group, and each R4 independently represents a hydroxyl group or a —OR5 group (wherein R5 represents a group selected from the group consisting of a C1-C10 aliphatic hydrocarbyl group, a C6-C10 aryl group, a —R6COOH group and a derivative thereof, and a —CH2—O—CH2—CH(OH)—CH2—OR7 group, wherein R6 represents a C1-C10 aliphatic hydrocarbylene group and R7 represents a C1-C10 aliphatic hydrocarbyl group or a C6-C10 aryl group), provided that all of R1, R2, and R3 are not simultaneously hydrogen atoms; and 10?x?10,000 and 0?y?10,000.

Abstract: A composition is provided that includes a polymer matrix. A core having a core surface is embedded within the polymer matrix. A polymeric ligand passivates the core surface and has a moiety Y, where Y is a Diels-Alder group of a diene or dienophile. A polymeric linker has a complementary Diels-Alder group diene or dienophile to moiety Y and forms a Diels-Alder bond with the moiety Y. A composition is also provided that includes polymer matrix having a matrix surface. A core having a core surface is present on the matrix surface. A polymeric ligand passivates the core surface and has a moiety Y, where Y is Diels-Alder group of a diene or dienophile. The polymer matrix and polymeric ligand together define a matrix-ligand Flory-Huggins binary interaction function greater than 0.

Abstract: Biodegradable poly(ester-amides) are synthesized from amino acids, diols and dicarboxylic acids where one or both of the diols and dicarboxylic acids contain unsaturation; e.g., from di-p-nitrophenyl dicarboxylates and p-toluenesulfonic acid salts of bis(alpha-amino acid) disesters of diols where one or both of the dicarboxylate and diol moieties contain unsaturation or from di-p-nitrophenyl dicarboxylates, and p-toluene-sulfonic acid salts of bis(alpha-amino acid) diesters of diols and p-toluenesulfonic acid salt of lysine ester where one or both of the dicarboxylate and diol moieties contain unsaturation. The polymers are useful as biodegradable carriers for drugs of other bioactive agents.